<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762591</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-103-036</org_study_id>
    <nct_id>NCT02762591</nct_id>
  </id_info>
  <brief_title>Expanded Access of Pimavanserin for Patients With PD Psychosis</brief_title>
  <official_title>Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACADIA Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACADIA Pharmaceuticals Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this program is to provide patients with PDP access to pimavanserin until the&#xD;
      product receives marketing approval from the FDA and is commercially available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Parkinson's Disease Psychosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin tartrate</intervention_name>
    <description>Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient meets one of the following criteria:&#xD;
&#xD;
               1. Patient has participated in a previous study of pimavanserin for Parkinson's&#xD;
                  disease psychosis (PDP)&#xD;
&#xD;
               2. New (&quot;De novo&quot;) patients&#xD;
&#xD;
          2. A clinical diagnosis of Parkinson's disease with a minimum duration of 1 year&#xD;
&#xD;
          3. Female patients must be of non-childbearing potential&#xD;
&#xD;
          4. Psychotic symptoms must have developed after Parkinson's disease diagnosis was&#xD;
             established&#xD;
&#xD;
          5. Patient that has received stereotaxic surgery for subthalamic nucleus deep brain&#xD;
             stimulation must be at least 6 months post-surgery and the stimulator settings must&#xD;
             have been stable for at least 1 month prior to Study Day 1 (Baseline) and must remain&#xD;
             stable during the trial&#xD;
&#xD;
          6. The patient or Legally Authorized Representative (LAR) is willing and able to provide&#xD;
             consent&#xD;
&#xD;
          7. The patient or LAR is willing and able to adequately communicate in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has a history of significant psychotic disorders prior to or concomitantly&#xD;
             with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia&#xD;
             or bipolar disorder&#xD;
&#xD;
          2. Patient has had dementia prior to or concurrently with their diagnosis of Parkinson's&#xD;
             disease that may be inconsistent with a Parkinson's diagnosis&#xD;
&#xD;
          3. Patient has current evidence of a serious and/or unstable cardiovascular, respiratory,&#xD;
             gastrointestinal, renal, hematologic, or other medical disorder, including cancer or&#xD;
             malignancies, which would affect the patient's ability to participate in the program&#xD;
&#xD;
          4. Patient has had a myocardial infarction in last six months&#xD;
&#xD;
          5. Patient has any surgery planned during the screening, treatment, or follow-up periods&#xD;
&#xD;
        Patients will be evaluated at screening to ensure that all criteria for study participation&#xD;
        are met. These evaluations will include specific measures of psychosis severity, delirium,&#xD;
        dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the&#xD;
        study based on these assessments (and specifically if it is determined that their baseline&#xD;
        health and psychiatric condition do not meet all pre-specified entry criteria).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

